Democracy Spraffa

Appendix 3 2023-24 Sustainability and New Medicines Funding - letter to Territorial CEs - 14 Jun 23

Argyll and Bute Council · 27 September 2023
Back to Argyll and Bute HSCP Integration Joint Board (IJB) — 27 September 2023 and its agenda

Text extracted from the council's PDF. Layout and reading order may differ from the original.

Original council PDF · Download plain text

Page 1

St Andrew’s House, Regent Road, Edinburgh  EH1 3DG
www.gov.scot

 
Health Finance, Corporate Governance & Value
Directorate 
Richard McCallum, Director 
T: 0131-244 3475 
E: richard.mccallum@gov.scot 

Territorial NHS Chief Executives
cc
Territorial NHS Directors of Finance 
via email 
14th June, 2023 
Chief Executives 
2023-24 Sustainability and New Medicines Funding 
I am writing to inform you of further funding being allocated to support the 2023-24 finanical position. 
There are two parts to this funding as set out below. 
New Medicines (VPAS)
Boards should assume a further £100 million of new medicines funding in 2023-24 on a NRAC basis. 
This will bring the total allocation of funding to £250 million.  The final amount is still to be confirmed
however we wish to allocate this funding as early as possible in the financial year to allow certainty
for service planning.  Due to uncertainty about the replacement of the current VPAS arrangement,
this increase should be assumed on a non-recurring basis. 
NRAC Parity and Sustainability 
The annex to this letter also sets out the additional allocation of recurring funding which will be
allocated on an NRAC basis, with weighting to Boards behind NRAC parity, bringing those Boards to
0.6% from parity.  We will continue to review the NRAC position and intend to make incremental
reductions in parity distance in the coming years. 
This funding is predicated on NHS Boards continuing to work towards delivery of 3% recurring
savings in year supported by local and national Sustainability & Value arrangements.  I expect this
increased funding and associated benefit is fully reflected in 2023-24 forecasts.  We will shortly be
undertaking a detailed Quarter One review alongside Directors of Finance and teams. 
Yours sincerely 
Richard McCallum
Director of Health Finance and Governance

Page 2

St Andrew’s House, Regent Road, Edinburgh  EH1 3DG
www.gov.scot

 
Annex: Breakdown of Additional Sustainabiity and NRAC Parity Funding 
Figures in £ million NRAC
Allocation
NRAC Parity
adjustment Total
NHS Ayrshire & Arran 5.2 0.5 5.6         
NHS Borders 1.5 1.0 2.5         
NHS Dumfries & Galloway 2.1 0.0 2.1         
NHS Fife 4.8 3.5 8.3         
NHS Forth Valley 3.9 2.7 6.5         
NHS Grampian 6.9 1.1 8.0         
NHS Greater Glasgow & Clyde 15.6 0.0 15.6       
NHS Highland 4.6 3.4 8.0         
NHS Lanarkshire 8.7 6.3 14.9       
NHS Lothian 10.6 7.7 18.4       
NHS Orkney 0.4 0.3 0.6         
NHS Shetland 0.3 0.0 0.3         
NHS Tayside 5.5 3.1 8.6         
NHS Western Isles 0.5 0.0 0.5         
Total 70.5 29.5 100.0